Relaxation of vascular smooth muscle by cicletanine in aged wistar aorta under stress conditions - Importance of nitric oxide

被引:8
作者
Chamiot-Clerc, P
Choukri, N
Legrand, M
Droy-Lefaix, MT
Safar, ME
Renaud, JF
机构
[1] Hop Marie Lannelongue, Dept Rech Med, F-92350 Le Plessis Robinson, France
[2] INSERM U337, Paris, France
[3] Inst IPSEN, Paris, France
[4] Hop Broussais, Serv Med Interne, F-75674 Paris, France
关键词
cicletanine; aorta; endothelium; hypoxia;
D O I
10.1016/S0895-7061(99)00167-3
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
The vascular mechanism of action of cicletanine, an antihypertensive agent, was studied on isolated Wistar rat aortas (24-months-old) in presence and in absence of endothelium in two different stress conditions, normoxic and hypoxic, in presence of norepinephrine (NE). Under normoxic conditions, in presence of endothelium, cicletanine (10(-9)-10(-5)M) induced a concentration-dependent relaxation, whereas in absence of endothelium, cicletanine (10(-9)-10(-5)M) was ineffective although it relaxed the smooth muscle at higher concentrations (10(-4)M). At pharmacologic concentrations (below or equal 10(-5)M), relaxation induced by cicletanine, in presence of endothelium, was prevented by NO-nitro-L-arginine (L-NNA) (P < .005) and relaxation induced by the highest concentration (10(-4)M) was reversed by BaCl2 (P < .005). Under hypoxic conditions, in presence of NE and endothelium, the aorta displayed an increased developed tension that was significantly (P < .05) attenuated by cicletanine (10(-5)M) and insensitive to indomethacine (10(-7)M). When the two compounds were added together, the relaxation induced by cicletanine was significantly improved (P <. 005). These results indicated that cicletanine, under stress conditions, relaxes vascular smooth muscle through an endothelium-dependent action mediated by the nitric oxide (NO) synthase pathway. We proposed that the observed vascular effects could be associated with the counter-regulation mechanisms linked to the antihypertensive action of cicletanine. (C) 2000 American Journal of Hypertension, Ltd.
引用
收藏
页码:208 / 213
页数:6
相关论文
共 21 条
[1]  
[Anonymous], 1994, Textbook of Hypertension
[2]  
BOURGAIN RH, 1988, DRUG EXP CLIN RES, V14, P135
[3]  
BOUTHIER JA, 1988, DRUG EXP CLIN RES, V14, P221
[4]  
BUCCHOLZ R, 1992, DRUG DEVELOP RES, V25, P125
[5]  
CLOSTRE F, 1988, DRUG EXP CLIN RES, V14, P73
[6]   BLOOD-PRESSURE, STROKE, AND CORONARY HEART-DISEASE .2. SHORT-TERM REDUCTIONS IN BLOOD-PRESSURE - OVERVIEW OF RANDOMIZED DRUG TRIALS IN THEIR EPIDEMIOLOGIC CONTEXT [J].
COLLINS, R ;
PETO, R ;
MACMAHON, S ;
HEBERT, P ;
FIEBACH, NH ;
EBERLEIN, KA ;
GODWIN, J ;
QIZILBASH, N ;
TAYLOR, JO ;
HENNEKENS, CH .
LANCET, 1990, 335 (8693) :827-838
[7]  
FREDJ G, 1988, DRUG EXP CLIN RES, V14, P181
[8]   EVIDENCE FOR (+)-CICLETANINE SULFATE AS AN ACTIVE NATRIURETIC METABOLITE OF CICLETANINE IN THE RAT [J].
GARAY, RP ;
ROSATI, C ;
FANOUS, K ;
ALLARD, M ;
MORIN, E ;
LAMIABLE, D ;
VISTELLE, R .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 274 (1-3) :175-180
[9]  
JUNGERS P, 1988, DRUG EXP CLIN RES, V14, P189
[10]  
KOLTAI M, 1990, CLIN PHARM, V7, P106